1. Home
  2. AI vs TRVI Comparison

AI vs TRVI Comparison

Compare AI & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C3.ai Inc.

AI

C3.ai Inc.

SELL

Current Price

$11.07

Market Cap

2.0B

Sector

Technology

ML Signal

SELL

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

SELL

Current Price

$13.30

Market Cap

1.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AI
TRVI
Founded
2009
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
AI
TRVI
Price
$11.07
$13.30
Analyst Decision
Sell
Strong Buy
Analyst Count
13
11
Target Price
$8.90
★ $28.18
AVG Volume (30 Days)
★ 3.8M
1.5M
Earning Date
12-02-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.91
EPS
N/A
★ N/A
Revenue
★ $250,268,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.76
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$7.68
$9.82
52 Week High
$16.40
$20.22

Technical Indicators

Market Signals
Indicator
AI
TRVI
Relative Strength Index (RSI) 42.81 46.21
Support Level $11.07 $13.00
Resistance Level $11.14 $13.55
Average True Range (ATR) 0.54 0.88
MACD -0.08 0.06
Stochastic Oscillator 0.33 21.47

Price Performance

Historical Comparison
AI
TRVI

About AI C3.ai Inc.

C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions, namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications; C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications; and C3 Generative AI, which combines the utility of large language models. Geographically, the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: